Braskem (BRKM5) Q4 2025 earnings summary

Executive summary

• 2025 was marked by a prolonged global petrochemical downcycle, with recurring consolidated EBITDA at US$557 million, down 49% year-over-year, and a consolidated net loss of R$10,961 million, mainly due to a deferred tax asset write-off and impairment charges.

• Corporate leverage rose to 14.74x, with gross debt at US$9.4 billion and negative equity of R$16,502 million; material uncertainty exists regarding going concern due to liquidity pressures and negative working capital.

• Utilization rates and sales volumes declined across all regions, with Brazil and Mexico impacted by maintenance shutdowns and weak demand, while the U.S. & Europe segment posted negative EBITDA.

• Management is pursuing capital structure reorganization, liquidity preservation, and transformation initiatives, with ongoing negotiations for a potential change in controlling shareholder and financial restructuring at Braskem Idesa.

• Regulatory advances included PRESIQ and expanded REIQ benefits to support the Brazilian chemical sector, and significant provisions and settlements related to the Alagoas geological event.

Financial highlights

• Q4 2025 recurring consolidated EBITDA was US$109 million; full-year recurring EBITDA was US$557 million, with a margin of 4.4%.

• Net revenue for 2025 was R$70,717 million, down 8.7% year-over-year; gross profit dropped to R$1,556 million.

• Operating cash flow for Q4 was US$13 million generated; full-year operating cash consumption was US$246 million.

• Corporate cash at year-end was approximately US$2.1 billion, including a US$1 billion stand-by facility maturing in December 2026.

• Total debt at year-end was US$9.4 billion, with adjusted net debt at US$7.5 billion.

Outlook and guidance

• Management expects continued industry challenges due to global oversupply, weak demand, high debt service, and volatile input costs.

• Strategic focus for 2026–2028 includes capital structure reorganization, resilience, transformation, and sustainability initiatives, leveraging regulatory incentives.

• 2026 investments are projected at US$465 million, 31% below the six-year historical average.

• Ongoing negotiations for a potential change in controlling shareholder and financial restructuring at Braskem Idesa.

• No formal EBITDA guidance, but external consultancies expect spreads to recover if geopolitical risks subside.